Skip to main content
Premium Trial:

Request an Annual Quote

SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating

NEW YORK – Investment bank SVB Leerink on Tuesday initiated coverage of Twist Bioscience with a Market Perform rating and a price target on the firm's shares of $90.

The San Francisco-based synthetic biology company "is driving significant scale and lowering costs of synthetic DNA fragments (oligos) that form key ingredients of rapidly growing applications and massive end markets from next-generation sequencing, synthetic biology, [and] antibody drug discovery to emerging DNA data storage," analyst Puneet Souda wrote in a research note. He added that the firm's current share price already reflects expectations of growth into those end markets, leading to the Market Perform rating, but he was "inclined to revisit at a more attractive valuation."

Twist raised more than $344 million in public stock offerings, including its IPO, since 2018.

The firm's biopharma division is "a fast-developing major growth driver" and accounts for 25 percent of the company valuation but could take years to ramp up and will likely require drug approvals down the line, Souda wrote.

The analyst noted that Twist currently has six DNA "writers" giving it $200 million in revenue output capacity.

In morning trading on the Nasdaq, shares of Twist were up less than 2 percent at $94.43.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.